A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study

奥西默替尼 医学 肺癌 内科学 中止 肿瘤科 回顾性队列研究 无进展生存期 临床试验 腺癌 癌症 化疗 ROS1型
作者
Chung‐Shien Lee,Iman Zaky Ahmed,Emily Miao,Shirley Chung,Khilna Patel,Nina Kohn,Nagashree Seetharamu
出处
期刊:Journal of Oncology Pharmacy Practice [SAGE Publishing]
卷期号:28 (5): 1140-1151 被引量:9
标识
DOI:10.1177/10781552211020798
摘要

The recently published FLAURA trial demonstrated that osimertinib has remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). While this has transformed current practice, there are no effective treatments following progression on osimertinib. The aim of our study was to compare progression-free survival (PFS) and overall survival (OS) between patients initiated on osimertinib to those started on other EGFR TKIs.This was a multicenter, retrospective study conducted at two large academic centers. Adult patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received EGFR therapy between 2014 and 2019 were included. Patients were dichotomized based on front-line TKI (osimertinib vs. other). PFS, OS, and time-to-discontinuation were evaluated.One-hundred seventy-two patients were included in the final analysis. Fifty-two (30.2%) patients received osimertinib and 120 (69.8%) patients received another EGFR TKI. The PFS rates at 6, 12, and 18 months were 86.3%, 79.5%, 69.8% in the osimertinib group and 86.6%, 64.2%, 39.3% in the other EGFR TKI group, respectively (p < 0.0036).Estimated OS at 6, 12, and 18 months was similar for both groups: 94.2%, 94.2%, 80.2% and 95.7%, 93.9%, 84.1%, respectively [Adjusted HR = 0.95 (95% CI, 0.37-2.44; p < 0.9128].Osimertinib demonstrated greater 12 and 18 month PFS compared to other EGFR TKIs. This finding is consistent with results of the FLAURA trial. However, unlike FLAURA, there were no differences in estimated OS between the two groups in our study. Further research to evaluate optimal sequencing strategies in the real world of first, second and third generation TKIs is needed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
刚刚
包包琪发布了新的文献求助10
1秒前
2秒前
科研怪完成签到 ,获得积分10
2秒前
淬h发布了新的文献求助10
3秒前
朝朝发布了新的文献求助10
3秒前
4秒前
超级炎彬发布了新的文献求助30
5秒前
5秒前
5秒前
5秒前
6秒前
reirei应助张俊敏采纳,获得10
7秒前
活力菠萝完成签到,获得积分10
8秒前
传奇3应助向北游采纳,获得10
8秒前
8秒前
乔垣结衣发布了新的文献求助30
9秒前
9秒前
10秒前
11秒前
11秒前
上官若男应助zhuan采纳,获得10
11秒前
11秒前
王梦豪发布了新的文献求助10
12秒前
pugongying完成签到,获得积分10
12秒前
1111完成签到,获得积分10
12秒前
ZQP发布了新的文献求助10
12秒前
科目三应助wx采纳,获得300
13秒前
liupangzi完成签到,获得积分10
13秒前
Zhang发布了新的文献求助10
13秒前
14秒前
Amanda发布了新的文献求助10
14秒前
小雨点完成签到 ,获得积分10
14秒前
大模型应助hqq采纳,获得10
15秒前
好好完成签到,获得积分10
15秒前
蒙蒙完成签到,获得积分10
16秒前
KUZ完成签到,获得积分20
16秒前
王磊完成签到,获得积分10
17秒前
17秒前
淬h完成签到,获得积分10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970048
求助须知:如何正确求助?哪些是违规求助? 3514739
关于积分的说明 11175783
捐赠科研通 3250115
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804951